Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Executive Promotions at PTC Therapeutics | Contract Pharma

What are you searching for?

Sign in
Promotions & Moves

Executive Promotions at PTC Therapeutics

Souza named chief operating officer, Utter named principal financial officer and treasurer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

PTC Therapeutics, Inc. has appointed Marcio Souza chief operating officer and Christine Utter was named principal financial officer and treasurer.

Mr. Souza joined the company in July 2014 as vice president of global marketing and served as senior vice president and head of Global Product Strategy since June 2016, where he was responsible for serving as the chair the integrated program teams as well as leading the global marketing, market access and health economics areas.  

Ms. Utter joined the company in 2010 as the assistant controller and advanced to her most recent position as senior vice president, Finance, in January 2017. From 2005 until 2009, Ms. Utter was the assistant corporate controller of Barrier Therapeutics.

“I am extremely pleased to announce these promotions. Both Marcio and Christine have been instrumental in the growth of PTC into a global organization with multiple products.  In his tenure at the company, Marcio has demonstrated expertise in product launches and strategic leadership capabilities across our corporate and commercial planning efforts,” said Stuart Peltz, Ph.D., chief executive officer, PTC Therapeutics, Inc. “Since joining PTC, Christine has been an invaluable asset to PTC and leads a strong financial team with broad public company expertise. These promotions increase our operational and strategic efforts for continued commercial growth to deliver on our mission to develop and commercialize innovative therapies for Duchenne muscular dystrophy and other rare diseases.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters